You are here

Use of Highly Porous Polymer Beads to Remove Anti-A and Anti-B Antibodies from Plasma for Transfusion

Award Information
Agency: Department of Defense
Branch: Defense Health Agency
Contract: W81XWH-17-C-0053
Agency Tracking Number: H2-0204
Amount: $999,070.00
Phase: Phase II
Program: STTR
Solicitation Topic Code: DHP15B-001
Solicitation Number: 2015.0
Timeline
Solicitation Year: 2017
Award Year: 2017
Award Start Date (Proposal Award Date): 2017-05-15
Award End Date (Contract End Date): 2019-10-14
Small Business Information
7 Deer Park Drive, Suite K
Monmouth Junction, NJ 08852
United States
DUNS: 830014077
HUBZone Owned: No
Woman Owned: No
Socially and Economically Disadvantaged: No
Principal Investigator
 Phillip Chan, MD, PhD
 Chief Executive Officer
 (732) 398-5426
 pchan@cytosorbents.com
Business Contact
 James Cason
Phone: (732) 398-5427
Email: jcason@cytosorbents.com
Research Institution
 Penn State University
 Sue   Lavan
 
Old Main
State College, PA 16802
United States

 (814) 865-7650
 Nonprofit college or university
Abstract

Plasma from AB donors is considered universal as it can be transfused regardless of recipient blood type and is frequently used to rapidly resuscitate massively bleeding hospital trauma patients and warfighters with combat casualties. However supplies can be rapidly depleted as AB donors make up only 4% of the population. Therefore robust a technology to cost-effectively generate universal plasma from any donor is of great importance. We propose the development of a light-weight, biocompatible filter, composed of a highly porous polymer to remove anti-A and anti-B antibodies from plasma. This small, light-weight filter will convert the plasma from donors of any blood type into universal plasma while maintaining levels of beneficial plasma factors without the use of expensive, complex biological ligands that could degrade or leach from the column. The outcome will be the development of a safe, easy-to-use, cost-effective filter that can simplify logistics, reduce transfusion costs and eliminate risk from transfusion errors caused by ABO incompatibility, providing a significant clinical benefit to patients treated at emergency trauma centers but particularly for logistically-constrained, advanced military surgical units. The widespread availability of universal plasma has the potential to significantly advance early resuscitative treatment protocols for massive trauma patients.

* Information listed above is at the time of submission. *

US Flag An Official Website of the United States Government